Textbook of Melanoma

por Hubner, R, Gore, M
Publicado 2004

Survival from melanoma of the skin in England and Wales up to 2001

por Ottensmeier, C H, Gore, M
Publicado 2008

Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies

por Gore, M E, Larkin, J M G
Publicado 2011

Antibody-dependent-cellular-cytotoxicity against cultured human breast cancer cells mediated by human effector cells using monoclonal and polyclonal antibodies.

por Gore, M. E., Skilton, R. A., Coombes, R. C.
Publicado 1983

Impact of enteral nutrition on nitrogen balance in patients of trauma

por Jivnani, Sabita, Iyer, Sandhya, Umakumar, Kabeer, Gore, M A
Publicado 2010

Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2.

por Gooding, R., Riches, P., Dadian, G., Moore, J., Gore, M.
Publicado 1995

Diabetes and Heart Failure in Patients With Coronary Disease: Separating Markers From Mediators

por McGuire, Darren K., Gore, M. Odette, Masoudi, Frederick A.
Publicado 2010

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib

por Mickisch, G, Gore, M, Escudier, B, Procopio, G, Walzer, S, Nuijten, M
Publicado 2010

A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily.

por Savage, P., Horton, V., Moore, J., Owens, M., Witt, P., Gore, M. E.
Publicado 1996

Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial

por Rothermundt, C, Hubner, R, Ahmad, T, Gibbens, I, Keyzor, C, Habeshaw, T, Kaye, S, Gore, M
Publicado 2006

The place of VEGF inhibition in the current management of renal cell carcinoma

por Nathan, P, Chao, D, Brock, C, Savage, P, Harries, M, Gore, M, Eisen, T
Publicado 2006

Repeat administration of high dose melphalan in relapsed myeloma.

por Mansi, J. L., Cunningham, D., Viner, C., Ellis, E., Meldrum, M., Milan, S., Gore, M.
Publicado 1993

Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.

por Lakhani, S., Selby, P., Bliss, J. M., Perren, T. J., Gore, M. E., McElwain, T. J.
Publicado 1990

Cisplatin/carboplatin cross-resistance in ovarian cancer.

por Gore, M. E., Fryatt, I., Wiltshaw, E., Dawson, T., Robinson, B. A., Calvert, A. H.
Publicado 1989

Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer

por Gore, M, Rustin, G, Schüller, J, Lane, S R, Hearn, S, Beckman, R A, Ross, G
Publicado 2001

Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma

por Geertsen, P F, Gore, M E, Negrier, S, Tourani, J M, von der Maase, H
Publicado 2004

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma

por Diem, S, Kasenda, B, Spain, L, Martin-Liberal, J, Marconcini, R, Gore, M, Larkin, J
Publicado 2016

Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma

por Waters, J S, Moss, C, Pyle, L, James, M, Hackett, S, A'Hern, R, Gore, M, Eisen, T
Publicado 2004

Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.

por Gore, M. E., Levy, V., Rustin, G., Perren, T., Calvert, A. H., Earl, H., Thompson, J. M.
Publicado 1995

Phase II trial of trimelamol in refractory ovarian cancer.

por Judson, I. R., Calvert, A. H., Gore, M. E., Balmanno, K., Gumbrell, L. A., Perren, T., Wiltshaw, E.
Publicado 1991